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Abstract
Retinitis pigmentosa (RP) is a group of inherited neurodegenerative diseases affecting photoreceptors and causing
blindness in humans. Previously, excessive activation of enzymes belonging to the poly-ADP-ribose polymerase (PARP)
group was shown to be involved in photoreceptor degeneration in the human homologous rd1 mouse model for RP. Since
there are at least 16 different PARP isoforms, we investigated the exact relevance of the predominant isoform - PARP1 - for
photoreceptor cell death using PARP1 knock-out (KO) mice. In vivo and ex vivo morphological analysis using optic
coherence tomography (OCT) and conventional histology revealed no major alterations of retinal phenotype when
compared to wild-type (wt). Likewise, retinal function as assessed by electroretinography (ERG) was normal in PARP1 KO
animals. We then used retinal explant cultures derived from wt, rd1, and PARP1 KO animals to test their susceptibility to
chemically induced photoreceptor degeneration. Since photoreceptor degeneration in the rd1 retina is triggered by a loss-
of-function in phosphodiesterase-6 (PDE6), we used selective PDE6 inhibition to emulate the rd1 situation on non-rd1
genotypes. While wt retina subjected to PDE6 inhibition showed massive photoreceptor degeneration comparable to rd1
retina, in the PARP1 KO situation, cell death was robustly reduced. Together, these findings demonstrate that PARP1 activity
is in principle dispensable for normal retinal function, but is of major importance for photoreceptor degeneration under
pathological conditions. Moreover, our results suggest that PARP dependent cell death or PARthanatos may play a major
role in retinal degeneration and highlight the possibility to use specific PARP inhibitors for the treatment of RP.
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Introduction
Blindness is a devastating condition that severely affects the
quality of human life. Retinitis pigmentosa (RP) is a group of
inherited neurodegenerative diseases that result in selective cell
death of photoreceptors and is regarded as the main cause of
blindness among the working age population in the developed
world [1]. Many of the genetic mutations causing RP have been
identified in recent years (for a recent list see RETNET webpage:
www.sph.uth.tmc.edu/retnet) but, nevertheless, the precise mech-
anisms eventually causing cell death remain unknown and to date
no adequate treatment for RP is available [2].
The retinal degeneration 1 (rd1 or rd) human homologous
mouse model for RP is characterized by a loss-of-function
mutation in the gene encoding for the b-subunit of rod
photoreceptor cGMP phosphodiesterase 6 (PDE6) [3]. The rd1
mouse is considered a relevant model for human RP, since about
4–5% of patients are suffering from mutations in the PDE6 beta
gene [4]. Non-functional PDE6 leads to accumulation of cGMP
which occupies a key role in the vertebrate phototransduction
cascade; however, excessively high cGMP levels trigger photore-
ceptor degeneration [5,6]. The rd1 mouse is one of the most
studied animal models for RP and previously we demonstrated an
involvement of excessive poly (ADP-ribose) polymerase (PARP)
activity in rd1 photoreceptor cell death [7].
PARP enzymes use NAD
+ as a substrate to transfer ADP-ribose
onto acceptor proteins [8,9]. There are at least 16 different PARP
isoforms among which PARP1 - one of the most abundant nuclear
enzymes - appears to be responsible for most of the cellular poly
(ADP-ribosy)lation activity [10]. PARP1 is activated by DNA
strand breaks and facilitates the DNA repair process [11,12]. On
the other hand, over-activation of PARP may lead to cell death
and PARP has been proposed to be a major constituent of a novel
cell death mechanism termed PARthanatos [13,14]. Accordingly,
pharmacological inhibition of PARP was shown to increase
cellular viability in a number of experimental systems and
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[11,15]. Similarly, PARP inhibition protected rd1 mouse photo-
receptors [7]. Notably, though, the question which PARP isoform
precisely was most important for the degeneration of photorecep-
tors remained open, which prevents the full understanding of the
pathology.
Here, we examined the phenotype of PARP1 KO retina in vivo,
ex vivo and in vitro. While, the retina of PARP1 KO animals
appeared essentially normal in terms of morphology and function,
photoreceptor cell death was greatly decreased under a specific
stress paradigm that mimics inherited retinal degeneration. These
results, for the first time, attribute an important role in
photoreceptor cell death to PARP1 specifically and emphasize
its importance for future treatments of RP.
Results
Comparative analysis of PARP1 KO retinal morphology
and function
An initial comparison of wt, rd1 and PARP1 KO ex vivo retinal
morphology revealed no major differences between the wt and
PARP1 KO and genotypes at P11 (data not shown) or at P30
(Fig. 1A–C), although at this age the ONL in PARP1 KO did not
completely reach the thickness of wt (wt:6 2mm 60.3 SEM, n=4,
rd1:8mm 60.3 SEM, n=3, PARP1 KO: 54 mm 60.6 SEM,
n=4; p,0.05) (Fig. 1D). The latter was also reflected in the
number of ONL photoreceptor rows (wt: 12.760.3 SEM, n=3,
rd1: 0.960.1 SEM, n=3, PARP1 KO: 11.560.3 SEM, n=4;
p,0.05). Consistent with these histological data, in vivo optic
coherence tomography (OCT) examination showed an apparently
normal retinal morphology and layering together with a somewhat
thinner ONL in PARP1 KO (Fig. 1E–G).
Absence of the characteristic 116 kDa band in PARP1 western
blot confirmed the deficiency in protein expression in PARP1 KO
(Fig. 1H). To test for possible alterations in retinal function of
PARP1 KO mice, single flash ERGs were recorded from PARP1
KO and wt control (SV129) mice under scotopic and photopic
conditions at an age of 5 weeks (Fig. 1I, J). Both rod and cone
photoreceptor signalling appeared to be normal in PARP1 KO,
since neither type of measurement revealed any signs of impaired
retinal function.
Cell death markers in wt, rd1 and PARP1 KO retina
In the rd1 mouse model, retinal degeneration starts at around
P11 [2] and consequently we chose this time-point for a
comparative analysis of different cell death markers in wt, rd1,
and PARP1 KO retina. cGMP levels were studied using
immunofluorescent detection with a selective and well validated
antibody [16] on ex vivo sections from wt, rd1 and PARP KO mice
at P11. While wt retina was essentially devoid of cGMP positive
cells, many positive cells were observed in rd1 ONL due to PDE6
dysfunction in this genotype (wt: 0.01% 60.004 SEM, n=4; rd1:
6.3% 60.9 SEM, n=4, p,0.01) (Fig. 2A, B). cGMP-positive cells
were rarely seen PARP1 KO (0.004% 60.003 SEM, n=5)
(Fig. 2C). Accumulation of cGMP corresponded to PDE6 beta
expression, which was readily detectable in photoreceptor outer
segments of both wt and PARP1 KO, but absent in the rd1
situation (Fig. S1).
The analysis of in situ PARP activity at P11 (Fig. 2D–F), showed
few PARP activity positive cells in the wt retina (0.02% 60.008
SEM, n=3), large numbers of PARP activity positive cells in rd1
ONL (2.6% 60.1 SEM, n=3), and no detectable activity in the
PARP1 KO (0.0% 60.0 SEM, n=3). Differences between
PARP1 KO and rd1 (p,0.01), and PARP1 KO and wt (p,0.05)
were statistically significant.
Accumulation of poly(ADP-ribosyl)ated proteins is considered
an indirect measure to confirm PARP activity. Previous studies
showed that PARP activity and correspondingly accumulation of
PAR were increased in rd1 photoreceptors at P11 [7]. In the
present study immunohistochemistry demonstrated very low levels
of PAR accumulation in the wt situation (0.02% 60.005 SEM,
n=6), high levels in rd1 ONL (1.5% 60.2 SEM, n=4), and no
detection in PARP1 KO (0.0% 60.0 SEM, n=5) (Fig. 2G–I).
There were significant differences between in vivo PARP1 KO and
rd1 (p,0.01) as well as PARP1 KO and wt (p,0.05). Western blot
analysis for PAR confirmed the immunohistochemical results
showing a strong accumulation of high molecular weight
poly(ADP-ribosyl)ated proteins only in rd1 retinal tissue samples
(Fig. 2O).
We then used the TUNEL assay to identify degenerating cells in
the different genotypes. In the ONL, wt retinae showed only very
few TUNEL positive, dying cells, while much higher numbers
were detected in the rd1 situation (wt: 0.1% 60.006 SEM, n=3;
rd1: 4.5% 60.4 SEM, n=3) (Fig. 2J, K). Similar to wt, PARP1
KO retinae showed very low numbers of TUNEL positive cells
(PARP1 KO: 0.04% 60.01 SEM, n=3) (Fig. 2L). Quantification
and statistical analysis revealed no significant difference (p=0.31)
between wt and PARP1 KO but a significant difference (p,0.01)
between PARP1 KO and rd1 (Fig. 2M). In line with the
histological data, these results indicated that there was no major
degeneration phenotype in the ONL of PARP1 KO, which
therefore, in all aspects studied here, appeared to behave like wt.
PARP1 KO reduces photoreceptor cell death induced by
PDE6 inhibition
Zaprinast is a selective PDE5/6 inhibitor [17,18] which in a
concentration dependent manner raises intracellular cGMP levels
and causes cGMP-dependent photoreceptor degeneration closely
resembling the rd1 degeneration (Fig. S2) [6,19]. Here, 100 mM
zaprinast was used to mimic the rd1 situation on wt and PARP1
KO retinal explants cultured between postnatal days 5–11.
Successful PDE6 inhibition was confirmed by an increased cGMP
immunofluorescence. While untreated wt retina is essentially
devoid of cGMP immunoreactivity (0.7% 60.4 SEM, n=5), the
zaprinast treated wt ONL showed large numbers of cGMP positive
cells (7.8% 60.1 SEM, n=4), comparable to the rd1 situation
(10.6% 60.7 SEM, n=7) (Fig. 3A–C). Untreated PARP1 KO
displayed very low cGMP immunoreactivity (0.2% 60.1 SEM,
n=3), which was strongly increased by zaprinast treatment (4.2%
60.3 SEM, n=4) (Fig. 3D, E). The zaprinast induced increase in
cGMP positivity was significantly lower in PARP1 KO when
compared to wt (p,0.01). However, in relative terms the zaprinast
induced elevation in cGMP was more pronounced in PARP1 KO
(21-fold increase) than in wt (11-fold increase).
Immunohistochemistry for PAR illustrated few positive cells in
the ONL of untreated wt situation (0.1% 60.02 SEM, n=3),
larger numbers of positive cells in zaprinast treated wt (0.7%
60.07 SEM, n=5) and rd1 ONL (1.3% 60.3 SEM, n=3), and
very few positive cells in untreated (0.05% 60.01 SEM, n=3,
p,0.05) and zaprinast treated PARP1 KO retinae (0.1% 60.02
SEM, n=3, p,0.05) (Fig. 3F–J).
The TUNEL assay for dying cells identified only very few
positive cell in P11 wt ONL in vitro (wt: 1.3% 60.1 SEM, n=3),
while zaprinast treatment raised their number to levels compara-
ble to untreated rd1 retina (wt + zaprinast: 3.9% 60.1 SEM, n=6;
rd1: 5.3% 60.3 SEM, n=5) (Fig. 3K–M). Untreated PARP1 KO
retina displayed very low numbers of TUNEL positive cells (0.6%
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PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e15495Figure 1. Histological and functional analysis of PARP1 KO retina. Haematoxylin/eosin staining at PN30 revealed normal morphology and
layering of wt (A) retina, while in the rd1 situation (B) the ONL had almost completely disappeared. In contrast, PARP1 KO retinae (C) appeared
essentially normal, although direct comparisons with wt showed lower PARP1 KO values for ONL thickness and number of photoreceptor rows
PARP1 in Retinal Function and Degeneration
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e1549560.1 SEM, n=3) similar to untreated wt. Importantly, zaprinast
treatment resulted only in a minor elevation of cell death in
PARP1 KO retina when compared to zaprinast treated wt
(PARP1 KO + zaprinast: 0.7% 60.04 SEM, n=5, p,0.01)
(Fig. 3N, O). In relative terms, zaprinast treatment resulted in a
200% elevation of cell death in wt retina, compared to only 17%
increase in PARP1 KO (Fig. 3P).
Together, these results suggest that the photoreceptor cell death
that follows upon PDE6 inhibition and subsequent accumulation
of cGMP, to a major extent is dependent on PARP1 activity, since
PARP1 KO displayed strong resistance to this paradigm of
induced photoreceptor degeneration.
Discussion
Cell death, in particular in the context of neurodegenerative
diseases, has frequently been found to be associated with excessive
PARP activity [10,11] and we have previously found strong PARP
activation to be causally connected to photoreceptor cell death [7].
Nevertheless, at the beginning of this study it was not clear which
one of the 16 different PARP isoforms might be responsible for this
detrimental effect. Here, we show that PARP activity during
photoreceptor neurodegeneration is caused to a major extent by
the PARP1 isoform specifically. While wt photoreceptors were
highly susceptible to a stress paradigm mimicking the rd1 type of
inherited retinal degeneration, PARP1 KO photoreceptors were
resistant to such stress.
PARP activity in cellular physiology
PARP enzymes play ambiguous roles in cellular physiology. They
are important mediators of DNA repair and strongly protect cells
against genotoxic stressors [20,21], notably because poly(ADP-
ribosyl)ation of DNA associated histones causes relaxation of the
chromatin structure, allowing DNA repair enzymes to access the site of
the strand break, thereby facilitating the DNA repair process [10,12].
On the other hand, an excessive PARP activation may overstrain the
cellular metabolism, leading to an energetic collapse and eventually cell
death [22,23]. In this respect excessive consumption of the PARP
substrate NAD
+ seems to be of particular importance, since this will
indirectly result in depletion of cellular ATP [10,22].
In conjunction with its antagonist poly-ADP-ribose-glycohy-
drolase (PARG), PARP activity may result in the generation of free
PAR polymers. These may cause release of a mitochondrial
protein termed apoptosis inducing factor (AIF) resulting in its
translocation to the nucleus, widespread DNA fragmentation and
cell death [24], as seen in PARP dependent cell death of primary
cortical neurons [25]. Alternatively, free PAR may act on
transient-receptor-potential (TRP) ion channels causing excessive
calcium influx [26,27] with potential repercussions on calcium-
dependent calpain-type protease activation and therefore photo-
receptor cell death [28]. Interestingly, auditory receptor cell death
following acoustic trauma and cochlear ischemia has also been
connected with excessive PARP activation, suggesting that sensory
cells might be particularly susceptible to undergo PARP dependent
cell death [29,30].
PARP1 KO mice develop normally and show no particular
phenotype. However, these animals are susceptible to developing
epidermal hyperplasia and obesity at older ages [31] and cells
lacking PARP1 are susceptible to genotoxic stress [21]. Future
investigations will have to determine whether reduced DNA repair
capabilities, or other PARP related actions, are responsible for the
slight decrease in retinal thickness observed in PARP1 KO
animals. Interestingly, PARP1 KO animals display increased
resistance to streptozotocin induced cell death of pancreatic beta
cells [32], ischaemic brain injury [33], and ocular deprivation
induced cell death in the lateral geniculate nucleus [34]. Indeed,
PARP is supposed to play a central role in a novel form of caspase-
independent cell death which involves excessive activation of
PARP, formation of poly-ADP-ribose polymers, translocation of
AIF protein from mitochondria to the nucleus, chromatin
condensation, and large DNA fragmentation. Because of its
dependence on PARP activity and the generation of PAR
polymers this cell death mechanism was tentatively termed
PARthanatos [13,35]. Taken together, PARP1, apart from its
functions during normal cell physiology appears to be of major
importance for cell death, particularly in neuronal cells.
PARP and photoreceptor cell death mechanisms
It has previously been shown that photoreceptor cell death in the
rd1 mouse is associated with nuclear translocation of AIF [36] and
oxidative DNA damage, factors which both colocalizes with PARP
activity in photoreceptor nuclei [7]. Our finding that PARP1 KO
photoreceptors are highly resistant to PDE6 inhibition induced
degeneration confirms these previous results and points to the
PARP1 isoform as a major contributor to PARP dependent
photoreceptor cell death. However, while PARP1 KO dramatically
reduced the accumulation of PAR in all situations tested, PAR
accumulation was not abolished altogether. This suggests that other
PARP isoforms such as PARP2 [21,37,38,39] may, to a limited
extent, compensate for the lack of PARP1 expression.
Apart from PARP activity, photoreceptor cell death in the rd1
mouse model for RP has been found to be characterized by an
elevation of cGMP levels, activation of PKG, calpains and histone
deacetylases (HDACs) [5,6,40]. The PARP activity in rd1
photoreceptors might have a bearing on calpain activation [15]
and could itselfbe governed bythe activity ofHDACs,sinceHDAC
inhibition in rd1 retina also abolished PARP activity [38].
Moreover, deacetylation and poly(ADP-ribose)ylation were exactly
coincidental in degenerating rd1 photoreceptors [40] also suggesting
a sequential activation of first HDAC then PARP during cell death.
Even though photoreceptor degeneration has in the past often
been addressed as an apoptotic process, it takes place independent
of critical features of apoptosis such as de novo protein biosynthesis,
caspase activation, or cytochrome c release (reviewed in: 2). The
finding that photoreceptor degeneration induced by PDE6
inhibition was strongly reduced in PARP1 deficient animals
(quantification in D). SD-OCT in vivo imaging of wt (E), rd1 (F), and PARP1 KO (G) retinae showed a similar picture, with PARP1 KO retina appearing
slightly thinner than its wt counterpart. Absence of the 116 kDa PARP1 protein was confirmed using western blot (H). In spite of the subtle
morphological changes seen in PARP1 KO, functional in vivo analysis using ERG under both scotopic and photopic conditions in 5 weeks old animals
did not detect any differences between PARP1 KO (red traces) and wt control (black traces). In rd1 animals (blue traces), however, retinal function was
essentially abolished. Representative single flash ERG recordings from dark-adapted (top) and light-adapted (bottom) states are shown in (I), while a
statistical evaluation (box-and-whisker plot) of dark-adapted (scotopic; SC) and light-adapted (photopic; PH) single flash ERG b-wave amplitudesi n
wt, rd1, and PARP1 KO mice is shown in (J). Boxes indicate the 25% and 75% quantile range, whiskers indicate the 5% and 95% quantiles, and solid
lines connect the medians of the data. For each of the different experimental investigations, n=3–4 animals from each genotype were used and
analyzed independently. Error bars in (D) represent SEM. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer
plexiform layer; IS, inner segment; OS, outer segment; RPE, retinal pigment epithelium.
doi:10.1371/journal.pone.0015495.g001
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responsible for cell death in this situation. If this was the case then
in turn the wealth of knowledge available for the rd1 degeneration
might also be used to improve the understanding of this novel cell
death mechanism.
Conclusion
We have shown a causal involvement of PARP1 in a retinal
photoreceptor degeneration paradigm, that mimics inherited neuro-
degeneration as it occurs in the human homologous rd1 mouse
model. PARP1 KO prevented photoreceptor cell death in vitro,a
result that highlights the importance of PARP1 as a novel therapeutic
target in retinal degeneration both for pharmacological and genetic
treatment approaches. A reduced PARP1 activity would most likely
not compromise retinal function, since absence of PARP1 does not
alter retinal function. These findings also propose that photoreceptor
cell death may be governed by an alternative cell death mechanism,
possibly related to the recently described PARthanatos.
Figure 2. cGMP, PARP activity and TUNEL in wt, rd1, and PARP1 KO retina. At P11, immunoreactivity for cGMP was essentially absent in
both wt and PARP1 KO retina, while in the rd1 ONL a large number of photoreceptor cell bodies, neurites and segments were stained (A–C). The in
situ PARP activity assay (D–F) and accumulation of PAR (G–I) as an indirect marker for PARP activity labeled photoreceptor nuclei only in the rd1
situation but not in wt nor PARP1 KO retina. The bar graphs display the quantification of the percentages of ONL cells positive for cGMP and TUNEL
(M), and PARP activity and PAR accumulation (N), respectively. Strong accumulation of PAR in rd1 retina was confirmed using western blot (O). The
TUNEL assay for dying cells identified large numbers of cells only in the rd1 ONL (J–L), Retinae from n=3–6 animals were used for each analysis and
genotype. Error bars represent SEM.
doi:10.1371/journal.pone.0015495.g002
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PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e15495Figure 3. PARP1 KO animals are resistant to PDE6 inhibition induced photoreceptor cell death. Organotypic retinal explant cultures
obtained from wt and PARP1 KO animals were treated with the PDE6 inhibitor zaprinast and compared to untreated wt, rd1 and PARP1 KO cultured
retinae. Control wt retinae at P11 in vitro showed minimal immunoreactivity to cGMP-antibody in the ONL (A). Zaprinast treated wt retinae exhibited
strongly increased intracellular cGMP levels (B), similar to what was observed in PDE6 mutant rd1 retina (C). While PARP1 KO did not display cGMP
immunoreactivity (D), it responded to zaprinast treatment with a moderate, but significant, elevation of cGMP positive ONL cells (E). Accumulation of
PAR as an indirect marker for PARP activity (F–J) was found in large amounts only in zaprinast treated wt or rd1 ONL but notably absent in PARP1 KO
preparations and wt retinae. The TUNEL assay for dying cells generally followed a similar pattern (K–O): The rd1 mutant or PDE6 inhibition resulted in
marked increases of positive cells in the ONL only. The bar graph (P) illustrates the quantification of the three parameters assayed. Explant cultures
from n=3–6 animals were used for each treatment situation and genotype. Error bars represent SEM.
doi:10.1371/journal.pone.0015495.g003
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Experimental animals
Animals were housed under standard white cyclic lighting, had
free access to food and water, and were used irrespective of
gender. C3H rd1 mice [41], PARP1 KO mice [31] and wild-type
(wt) SV129 mice were used. All procedures were approved by the
Tu ¨bingen University committee on animal protection (Einrich-
tung fu ¨r Tierschutz, Tiera ¨rztlichen Dienst und Labortierkunde
directed by Dr. Franz Iglauer) and performed in accordance with
the ARVO statement for the use of animals in ophthalmic and
visual research. Protocols compliant with 14 of the German law on
animal protection were reviewed and approved by Dr. Ulf
Scheurlen and Dr. Susanne Gerold (Einrichtung fu ¨r Tierschutz,
Tiera ¨rztlichen Dienst und Labortierkunde; Registration No.: 16/
12/08-1, 10/02/10-1). Since experiments were carried out on ex
vivo retinal explants (see below), no further permits were required.
Because in the rd1 retina critical changes are apparent at post-
natal day 11 (P11) [30,42], most comparisons were carried out at
this age.
Morphological characterization
Haematoxylin/Eosin staining was used for ex vivo characteriza-
tion of PARP1 KO retinae. Fixed cryosectioned retinae were
stained in Harris haematoxylin solution (Vector Laboratories, CA,
USA, H-3401) for 3 minutes and then washed in bidestilled water
for 1 minute. Following a brief, 2s exposure to 25% hydrochloric
acid in ethanol, the sections were washed again and counterstained
in Accustain eosin Y solution (Sigma-Aldrich, Munich, Germany,
HT-110-1-16) for 30 seconds to 1 minute. The sections were
dehydrated in a 70% –96% –100% alcohol series, washed in
xylene for 2 minutes, and then mounted with DPX mounting
medium for histology (Sigma-Aldrich).
Electroretinographic Analysis
Electroretinograms (ERGs) were recorded binocularly accord-
ing to previously described procedures [43,44]. The ERG
equipment consisted of a Ganzfeld bowl, a direct current
amplifier, and a PC-based control and recording unit (Multiliner
Vision; VIASYS Healthcare GmbH, Hoechberg, Germany). Mice
of 5 weeks age were dark-adapted overnight and anaesthetised
with ketamine (66.7 mg/kg body weight) and xylazine (11.7 mg/
kg body weight). The pupils were dilated and single flash ERG
responses were obtained under dark-adapted (scotopic) and light-
adapted (photopic) conditions. Light adaptation was accomplished
with a background illumination of 30 candela (cd) per square
meter starting 10 minutes before recording. Single white-flash
stimulus intensity ranged from 24 to 1.5 log cd*s/m
2 under
scotopic and from 22 to 1.5 log cd*s/m
2 under photopic
conditions, divided into 10 and 8 steps, respectively. Ten responses
were averaged with an inter-stimulus interval of either five seconds
or 17 seconds (for 0, 0.5, 1, and 1.5 log cd*s/m
2).
Spectral domain optical coherence tomography (SD-
OCT)
SD-OCT imaging was performed immediately following ERG,
i.e. animals remained anaesthetized. Mouse eyes were subjected to
SD-OCT using the commercially available Spectralis
TM
HRA+OCT device from Heidelberg Engineering (Heidelberg,
Germany) featuring a broadband superluminescent diode at
l=870 nm as low coherent light source. Each two-dimensional
B-Scan recorded at 30u field of view consisted of 1536 A-Scans,
which were acquired at a speed of 40,000 scans per second.
Optical depth resolution was approximately 7 mm with digital
resolution reaching 3.5 mm [45]. The adaptation for the optical
qualities of the mouse eye was described previously [46].
Retinal explant cultures
Organotypic retinal cultures that included the retinal pigment
epithelium (RPE) were prepared in principle as previously
published [47]. Briefly, P5 animals were sacrificed, the eyes
enucleated and pretreated with 12% proteinase K (ICN
Biomedicals Inc., OH, USA; 193504) for 15 minutes at 37uCi n
R16 serum free culture medium (Invitrogen Life Technologies,
Paisley, UK; 07490743A). Proteinase K was blocked by addition
of 10% fetal bovine serum, followed by rinsing in serum-free
medium. In the following, cornea, lens, sclera and choroid were
removed carefully, with only the RPE remaining attached to the
retina. The explant was then cut into four wedges to give a clover-
leaf like structure which was transferred to a culture membrane
insert (Millipore AB, Solna, Sweden; PIHA03050) with the RPE
facing the membrane. The membrane inserts were placed into six
well culture plates and 1.4 ml of R16 medium with supplements
[47] was added. The cultures were incubated at 37uCi na
humidified 5% CO2 incubator. The culture medium was changed
every 2 days during 6 culturing days. Retinal explants were left
without treatment for 2 days (until P7), followed by zaprinast (100
or 200 mM; Sigma Z0878) treatment. Zaprinast was prepared in
dimethyl sulfoxide (DMSO; Sigma D2650) and diluted in R16
serum free culture medium with supplements. For controls, the
same amount of DMSO was diluted in culture medium.
TUNEL Assay
The terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay was performed on cryosections from
treated/untreated wt, PARP1 KO, and rd1 retinae, using an in situ
cell death detection kit conjugated with fluorescein isothiocyanate
(Roche Diagnostics, Mannheim, Germany). For controls, terminal
deoxynucleotidyl transferase enzyme was either omitted from the
labelling solution (negative control), or sections were pre-treated
for 30 min with DNAse I (Roche, 3 U/ml) in 50 mM Tris-HCl,
pH 7.5, 1 mg/ml BSA to induce DNA strand breaks (positive
control). Negative control gave no staining at all, while positive
control stained all nuclei in all layers of the retina (not shown, see:
7).
Immunostaining
4% PFA fixed, frozen retinal sections from P11 animals or
cultured retinae, were dried for 30–60 minutes at 37uC.
Subsequently, the tissue was rehydrated in PBS, and pre-incubated
for 1 hour at RT in blocking solution, containing 10% normal
serum, and 0.1% or 0.3% Triton in PBS (PBST). Immunohisto-
chemistry was performed overnight at 4uC, using primary
antibodies directed against cGMP (obtained from Jan de Vente,
Maastricht University; see: 16; dilution 1:500), PAR (Alexis
Biochemicals, Lo ¨rrach, Germany; dilution 1:200; Order No.:
804-220), and PDE6 beta (Affinity Bioreagents; dilution 1:400;
Order No.: PA1-722) diluted in blocking solution. The tissue was
rinsed in PBST, and incubated for 1 hour with Alexa 488
conjugated secondary antibody, (1:200-1:750, Invitrogen), diluted
in PBST. Sections were rinsed in PBS, and mounted in
Vectashield with DAPI (Vector, Burlingame, CA, USA).
Western blot (WB)
Retinal tissue from PARP1 KO, wt and rd1 mice were
homogenized in buffer as described previously [7] with a Heidolph
DIAX 600 homogenizer (Heidolph, Schwabach, Germany) or a
PARP1 in Retinal Function and Degeneration
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determination of protein concentration. For separation of proteins,
SDS-PAGE 10–12% gradient gel (at 55 V) was used and 27 mg
protein was loaded per well. Subsequently, the proteins were
transferred to PVDF membranes (GE Healthcare, UK). Mem-
branes were blocked in Roti block (Roth, Karlsruhe, Germany)
blocking buffer for 1 hour at room temperature (RT). Membranes
were incubated in primary antibodies against PARP1 (BD
Pharmingen, Heidelberg, Germany; 556362), PAR (see above),
actin (Sigma-Aldrich; A 2668) at a dilution of 1:1000 in buffer
containing PBST and 5% dried milk (Roth) overnight at 4uC.
Membranes were washed with PBST and incubated with
horseradish peroxidase conjugated secondary antibody (GE
Healthcare, UK) for 1 hour at RT. Hyperfilm (GE Healthcare,
UK) detection system was used as a membrane developer. Films
were scanned and quantified using ImageJ (National Institutes of
Health, Washington, USA).
PARP activity assay
Eyes from PARP1 KO, wt and rd1 mice were enucleated, frozen
immediately on dry ice (272uC), followed by cryosectioning. A
biotin-avidin blocking kit (Vector) was used to block endogenous
biotin and to reduce background. After incubation with PARP
reaction mixture (10 mM MgCl2, 1 mM dithiothreitol, 5 mM
biotinylated NAD (Trevigen, Gaithersburg, MD, USA) in
100 mM Tris buffer with 0.2% Triton X100, pH 8.0) for 2.5 h
at 37uC, the sections were washed with PBS, 3 times for 5 minutes.
The biotin incorporated by PARP activity was then detected by
fluorescently labeled avidin (1:800 in PBS, 1 h at RT). After 3
times 5 min washing in PBS, the sections were mounted in
Vectashield (Vector). For controls, biotinylated-NAD
+ was omitted
from the reaction mixture resulting in absence of detectable
reaction product.
Microscopy, Cell counting, and Statistics
Microscopy was performed using a Zeiss Imager Z1 Apotome
Microscope. Images were taken with a Zeiss Axiocam digital
camera, using Zeiss Axiovision 4.7 software. Image enhancements
(Contrast, Colors) were done in paired fashion using Corel Draw
X3 software.
The percentages of ONL cells positive in the different assays
(PARP activity, PAR IHC, TUNEL) were assessed and calculated
in a blinded fashion as reported previously [6,28]. For each animal
the central areas (in proximity to the optic nerve) of at least 3
sections were quantified to yield an average value, and at least 3
different animals were analyzed for each time-point and genotype.
Values are given as mean 6 standard error of the mean (SEM).
Statistical analysis was performed using GraphPad Prism 4.01
software (GraphPad Software, La Jolla, CA, USA) and two-
tailed Student’s t test. Levels of significance were: * = p,0.05,
** = p,0.01, *** = p,0.001.
Supporting Information
Figure S1 PDE6 beta expression in wt, rd1, and PARP1
KO retinae. At PN11, immunostaining revealed PDE6 beta
expression (green) in photoreceptor outer segments of wt retina,
while PDE6 beta protein was undetectable in rd1 retina. In PARP1
KO retina PDE6 beta expression followed the pattern of wt. DAPI
(blue) was used as nuclear counterstain. The images shown are
representative for immunostainings performed on retinal cross-
sections from at least 3 different animals for each genotype.
Figure S2 Zaprinast treatment induces cGMP accumu-
lation and cell death in a concentration dependent
manner. Untreated organotypic retinal cultures derived from
wt animals showed very few cGMP (A) and TUNEL (D) positive
cells at P11 in vitro. PDE6 inhibition with zaprinast caused cGMP
accumulation (B, C) and cell death (E, F) that increased together
with zaprinast concentration (Quantification in G). Explant
cultures from n=3-8 wt animals were used for each treatment
situation. Error bars represent SEM.
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